LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

Search

Incyte Corp

Slēgts

SektorsVeselības aprūpe

83.1 -3.53

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

82.99

Max

83.49

Galvenie mērījumi

By Trading Economics

Ienākumi

247M

405M

Pārdošana

163M

1.2B

P/E

Sektora vidējais

20.463

35.664

EPS

1.16

Peļņas marža

33.319

Darbinieki

2,617

EBITDA

324M

582M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+1.08% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 28. okt.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

3.3B

17B

Iepriekšējā atvēršanas cena

86.63

Iepriekšējā slēgšanas cena

83.1

Ziņu noskaņojums

By Acuity

3%

97%

340 / 371 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

Incyte Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 12. sept. 22:41 UTC

Galvenie tirgus virzītāji

GlucoTrack Stock Falls on Plans to Sell $3 Million Note

2025. g. 12. sept. 16:04 UTC

Galvenie tirgus virzītāji

Upexi Shares Climb on Solana Gains

2025. g. 14. sept. 23:48 UTC

Tirgus saruna

Oil Futures Mixed Amid Divergent Signals -- Market Talk

2025. g. 14. sept. 23:41 UTC

Tirgus saruna

Gold Edges Lower on Likely Technical Correction -- Market Talk

2025. g. 14. sept. 23:38 UTC

Tirgus saruna

China's Economic Activity Data May Continue Reflecting Slowdown -- Market Talk

2025. g. 14. sept. 23:13 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 14. sept. 23:13 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

2025. g. 14. sept. 23:13 UTC

Tirgus saruna

Infratil May Need to Be More Aggressive With Asset Sales -- Market Talk

2025. g. 14. sept. 23:13 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 14. sept. 23:04 UTC

Tirgus saruna

Aristocrat's Interactive Unit Appears in Safe Hands -- Market Talk

2025. g. 13. sept. 08:20 UTC

Tirgus saruna
Peļņas

Tech, Media & Telecom Roundup: Market Talk

2025. g. 12. sept. 20:50 UTC

Tirgus saruna
Peļņas

Tech, Media & Telecom Roundup: Market Talk

2025. g. 12. sept. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 12. sept. 20:09 UTC

Peļņas

Correction to Opendoor Is Sliding. Don't Call It a Meme Stock, Says New Chairman. -- Barrons.com

2025. g. 12. sept. 19:23 UTC

Tirgus saruna

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

2025. g. 12. sept. 19:16 UTC

Tirgus saruna

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

2025. g. 12. sept. 19:03 UTC

Tirgus saruna

Natural Gas Futures Held Back By Plump Inventories -- Market Talk

2025. g. 12. sept. 18:59 UTC

Tirgus saruna

Dollar Pares Gains as Economy Keeps Showing Signs of Cooling -- Market Talk

2025. g. 12. sept. 18:38 UTC

Tirgus saruna
Peļņas

Adobe Seen Reaching Turning Point in AI Cycle -- Market Talk

2025. g. 12. sept. 18:33 UTC

Tirgus saruna

U.S. Oil Rig Count Rises By 2 to 416 -- Market Talk

2025. g. 12. sept. 18:22 UTC

Tirgus saruna

Canada's Divergence With US On Capex Spending is 'Appalling' -- Market Talk

2025. g. 12. sept. 16:56 UTC

Tirgus saruna

Renewable Fuels Association Calls for Nationwide E15 Following WASDE -- Market Talk

2025. g. 12. sept. 16:22 UTC

Peļņas

Adobe Earnings Were 'Solid.' Long-Term Growth Concerns Remain. -- Barrons.com

2025. g. 12. sept. 16:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 12. sept. 16:19 UTC

Iegādes, apvienošanās, pārņemšana

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

2025. g. 12. sept. 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 12. sept. 16:11 UTC

Peļņas

Novartis Catches a 'Sell.' Goldman Sachs Says the Stock Is Overvalued. -- Barrons.com

2025. g. 12. sept. 15:37 UTC

Tirgus saruna

Gold Holds Near All-Time Highs Ahead of Fed Meeting Next Week -- Market Talk

2025. g. 12. sept. 15:22 UTC

Tirgus saruna

European Gas Lifted by Geopolitical Risks But Storage Levels Ease Supply Fears -- Market Talk

2025. g. 12. sept. 15:07 UTC

Iegādes, apvienošanās, pārņemšana

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Incyte Corp Prognoze

Cenas mērķis

By TipRanks

1.08% augšup

Prognoze 12 mēnešiem

Vidējais 84 USD  1.08%

Augstākais 110 USD

Zemākais 60 USD

Pamatojoties uz 19 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Incyte Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

19 ratings

10

Pirkt

8

Turēt

1

Pārdot

Tehniskais rādītājs

By Trading Central

59.52 / 62.66Atbalsts un pretestība

Īstermiņā

Bullish Evidence

Vidējā termiņā

Bearish Evidence

Ilgtermiņā

Bearish Evidence

Noskaņojums

By Acuity

340 / 371 Rangs Veselības aprūpe

Ziņu noskaņojums

Ļoti spēcīga liecība "buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation
help-icon Live chat